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Summary
Smith-Lemli-Opitz syndrome is a frequently occurring
autosomal recessive developmental disorder character-
ized by facial dysmorphisms, mental retardation, and
multiple congenital anomalies. Biochemically, the dis-
order is caused by deficient activity of 7-dehydrocho-
lesterol reductase, which catalyzes the final step in the
cholesterol-biosynthesis pathway—that is, the reduction
of the D7 double bond of 7-dehydrocholesterol to pro-
duce cholesterol.We identified a partial transcript coding
for human 7-dehydrocholesterol reductase by searching
the database of expressed sequence tags with the amino
acid sequence for the Arabidopsis thaliana sterol D7-
reductase and isolated the remaining 5′ sequence by the
“rapid amplification of cDNA ends” method, or 5′-
RACE. The cDNA has an open reading frame of 1,425
bp coding for a polypeptide of 475 amino acids with a
calculated molecular weight of 54.5 kD. Heterologous
expression of the cDNA in the yeast Saccharomyces cer-
evisiae confirmed that it codes for 7-dehydrocholesterol
reductase. Chromosomalmapping experiments localized
the gene to chromosome 11q13. Sequence analysis of
fibroblast 7-dehydrocholesterol reductase cDNA from
three patients with Smith-Lemli-Opitz syndrome re-
vealed distinct mutations, including a 134-bp insertion
and three different point mutations, each of which was
heterozygous in cDNA from the respective parents. Our
data demonstrate that Smith-Lemli-Opitz syndrome is
caused by mutations in the gene coding for 7-dehydro-
cholesterol reductase.
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Introduction
Smith-Lemli-Opitz (SLO) syndrome (MIM 270400
[Smith et al. 1964; Opitz and de la Cruz 1994; Kelley
1997]) is an autosomal recessive disorder with an esti-
mated incidence of ∼1/20,000 births (Tint et al. 1994).
Patients with the disorder are characterized by a large
spectrum of developmental abnormalities, including se-
vere craniofacial malformations; multiple affected or-
gans, including the CNS and the brain; malformations
of the limbs; and incomplete development of the male
genitalia (Tint et al. 1995; Cunniff et al. 1997). In ad-
dition to these morphological abnormalities, patients
with SLO syndrome suffer from severe mental and
growth retardation and failure to thrive. On the basis
of the severity of the abnormalities, patients with SLO
syndrome have been subdivided into two groups—SLO
syndrome type I and SLO syndrome type II, the latter
being the more severe form, which often leads to death
shortly after birth (Donnai et al. 1986; Curry et al.
1987).
Biochemically, the disorder is caused by reduced/de-
ficient activity of 7-dehydrocholesterol reductase (7-
DHCR), the enzyme that catalyzes the reduction of the
C7-C8 (D7) double bond of 7-dehydrocholesterol (cho-
lesta-5,7-dien-3b-ol) to produce cholesterol (cholesta-5-
en-3b-ol)—that is, the ultimate step of the cholesterol-
biosynthetic pathway (Tint et al. 1994; Schefer et al.
1995). As a result, patients with SLO syndrome have
low plasma cholesterol and elevated 7-dehydrocholes-
terol concentrations, a characteristic used for the diag-
nosis of the syndrome. The link between this cholesterol-
biosynthesis defect and the multiple developmental
anomalies typical of SLO syndrome became clear after
the recent discovery that cholesterol plays an essential
role in animal embryonic development, in that it deter-
mines the spatial distribution of hedgehog proteins in
the developing embryo by tethering their N-terminal sig-
naling domain to the cell surface (Porter et al. 1996;
Tabin and McMahon 1997). This discovery initiated a
strongly increased interest in cholesterol and its role in
Figure 1 Nucleotide and deduced amino acid sequences of human 7-DHCR cDNA. 5′ and 3′ UTRs are denoted by lowercase letters.
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Table 1














Human 7-DHCR ) 38 37 34 30
A. thaliana sterol D7-reductase 56 ) 33 31 26
Human lamin B receptor 52 47 ) 40 33
S. cerevisiae sterol D14-reductase 49 49 55 ) 34
S. cerevisiae sterol D24(28)-reductase 43 41 49 49 )
NOTE.—Data above the diagonal are percentage of identity; and data below the diagonal are percentage of similarity.
development and established SLO syndrome as the pro-
totypical developmental disorder (Kelley et al. 1996;
Lanoue et al. 1997; Farese and Herz 1998). However,
it remained to be determined whether the reduced ac-
tivity of 7-DHCR is due to mutations in the gene coding
for 7-DHCR itself or in a gene coding for a protein that
regulates the activity or expression of 7-DHCR.
We here report the identification of a full-length cDNA
that codes for human 7-DHCR, as shown by heterolo-
gous expression in the yeast Saccharomyces cerevisiae.
The identification of distinct mutations in 7-DHCR
cDNA from different patients with SLO syndrome dem-
onstrates that SLO syndrome is caused by mutations in
the gene coding for 7-DHCR.
Patients and Methods
Patients
Patient 1 (SLO syndrome type I) was born at term to
unrelated parents. At birth, the boy was hypotonic and
showed microcephaly, micrognathia, craniofacial ab-
normalities, postaxial polydactyly of both hands, bilat-
eral syndactyly of the second and third toe, inguinal
testes and ambiguous genitalia that appeared to be a
severe hypospadias, and micropenis. Tube feeding was
started because of failure to thrive, and, at 1 year of age,
the patient showed severe developmental delay. SLO syn-
drome was biochemically diagnosed on the basis of low
plasma cholesterol and markedly-increased 7-dehydro-
cholesterol concentrations (0.595 and 0.559 mmol/liter,
respectively, determined 2 mo after birth) and was con-
firmed by the finding of very reduced 7-DHCR activity
in cultured skin fibroblasts, as determined on the basis
of 14C-mevalonate incorporation.
Patient 2 (SLO syndrome type II), the first child of
unrelated parents, had severe intrauterine growth retar-
dation and died, shortly after birth, of respiratory in-
sufficiency. The child showed multiple dysmorphic
features, including dysmorphic nose and ears, hypertro-
phied gingiva, retrognathia, unilateral hypoplastic fifth
finger, and syndactyly of the second and third toes. The
genitalia were documented as female, but chromosome
analysis revealed a 46,XY karyotype. Postmortem ex-
amination showed an atrial and ventricular septum de-
fect, unilateral abnormal pulmonary lobulation, and a
horseshoe kidney. SLO syndrome was biochemically di-
agnosed on the basis of elevated 7-dehydrocholesterol
concentrations determined in fibroblasts (7-dehydrocho-
lesterol/cholesterol ratio 0.032 [control .005]) and was
confirmed by the finding of a completely deficient 7-
DHCR activity in cultured skin fibroblasts, as deter-
mined by 14C-mevalonate incorporation.
Patient 3 (SLO syndrome type I), the fourth child of
unrelated parents, was born at term after a pregnancy
complicated by intrauterine growth retardation. At
birth, the boy was microcephalic and showed multiple
dysmorphic features, including a broad nasal tip with
anteverted nostrils, a cleft soft palate, broad alveolar
ridges, micrognathia, syndactyly of the second and third
toes, and a small penis with cryptorchidism. At 3 years
of age, the boy had psychomotor retardation, severe fail-
ure to thrive, and feeding difficulties that still necessi-
tated tube feeding. SLO syndrome was biochemically
diagnosed on the basis of low plasma cholesterol and
high 7-dehydrocholesterol concentrations (0.30 and
0.37 mmol/liter, respectively, determined 1 mo after
birth) and was confirmed by the finding of very reduced
7-DHCR activity in cultured skin fibroblasts, as deter-
mined by 14C-mevalonate incorporation.
Biochemical Methods
Cholesterol and 7-dehydrocholesterol concentrations
in plasma were determined as described by van Rooij et
al. (1997). 7-DHCR activities in cultured skin fibroblasts
were determined as described by Wanders et al. (1997).
Identification of 7-DHCR cDNA
By means of the BLAST algorithm (Altschul et al.
1990), the expressed sequence tag (EST) database of the
National Center for Biotechnology Information was
screened for sequences homologous to that of Arabi-
dopsis thaliana sterol D7-reductase. EST sequences were
grouped into three sets, and contigs were composed and
used to screen the GenBank protein database to identify
the candidate 7-DHCR sequence. Two EST clones (IM-
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Figure 2 Sequence alignment of human 7-DHCR and different sterol reductases. Amino acids conserved in three or more sequences are
boxed. Sequence designations are as follows: 1  human 7-DHCR; 2  A. thaliana sterol D7-reductase; 3  human lamin B receptor (C-
terminal 447 amino acids); 4  S. cerevisiae sterol D14-reductase; and 5  S. cerevisiae sterol D24(28)-reductase.
AGE Consortium Clone ID417125 and ID251607) for
which no 5′ end sequence had been deposited into the
database were ordered from the UK HGMP Resource
Centre in Cambridge and were entirely sequenced. The
remaining 5′ sequences were obtained by the “rapid am-
plification of cDNA ends” method (5′-RACE), by means
of two nested cDNA-specific primers complementary to
nucleotides 513–487 (5′-GAA CCA GGA CAG GAG
ATG AGC GTT TGC-3′) and 386–360 (5′-ACG TAG
CCG GGT AGA AAC TTA TGG CAG-3′), and from
leukocyte cDNA, according to the instructions of the
manufacturer (Clontech).
7-DHCR cDNA Expression in S. cerevisiae
The coding sequence of 7-DHCR was expressed under
the transcriptional control of the GAL1 promoter, by
means of the yeast expression vector pYES2 (Invitrogen).
The expression construct and, as a control, pYES2 with-
out insert were transformed separately into S. cerevisiae
strain INVSC2 (Invitrogen), by the lithium acetate
method (Invitrogen protocol). Yeast transformants were
grown at 30C in yeast nitrogen base medium (Difco)
supplemented with 20 mg histidine/ml, with either 2%
glucose (GAL1-promoter repression) or 2% galactose
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Table 2
Sterol Content of Glucose- or Galactose-Grown S. cerevisiae
Strains Transformed with Different Plasmids
PLASMID TYPE AND
CARBON SOURCE




Glucose 100 ND ND
Galactose 42 43 15
pYES2:
Glucose 100 ND ND
Galactose 100 ND ND




(GAL1-promoter induction) as the carbon source. In
induction experiments, cells were pregrown in glucose
medium, transferred by centrifugation to glucose me-
dium and galactose medium, harvested by centrifugation
after the cultures reached an optical density, at 600 nm,
of ∼1 (15–20 h of growth at 30C), and then were an-
alyzed for sterol content. In addition, glucose- and ga-
lactose-grown cells from the pYES2  7-DHCR trans-
formant were resuspended in 100 mM Tris/HCl buffer,
pH 7.5, and were disrupted by vigorous vortexing with
glass beads (5 times for 30 s at 4C). The resulting hom-
ogenates were incubated with 15 mM cholesta-5,7-dien-
3b-ol (Sigma; prepared as a 0.2 mM stock in 30%
2-hydroxypropyl-b-cyclodextrin [Fluka]) and 2 mM
NADPH at 37C for 3 h and subsequently were analyzed
for sterols. For sterol analysis, cells or homogenates were
saponified for 2 h at 70C in alkaline ethanol; sterols
were extracted with hexane, converted to trimethylsilyl
derivatives by means of bis(trimethylsilyl)trifluoroacet-
amide-trimethylchlorosilane (BSTFA-TMCS), and then
were analyzed by gas chromatography-mass spectome-
try (GC/MS).
Mutation Analysis
First-strand cDNA was synthesized from RNA iso-
lated from cultured primary skin fibroblasts (from all
three patients and the parents of patient 1) or leukocytes
(from the parents of patients 2 and 3), as described else-
where (IJlst et al. 1994). With the first-strand cDNA used
as template, the coding sequence of the 7-DHCR cDNA
was amplified by PCR in two overlapping fragments, by
means of two primer sets tagged with either a
“21M13” (5′-TGT AAA ACG ACG GCC AGT-3′) se-
quence or an “M13rev” (5′-CAG GAA ACA GCT ATG
ACC-3′) sequence. One fragment was obtained by means
of primer set DHCR58 to 38 (5
′-[-21M13]-GGT TCA
AGA AGG AAA AGT TCC C-3′) and DHCR828–810 (5
′-
[M13rev]-TGA CCA GGA CCA TGG CAT TG-3′), and
the other fragment was obtained by means of primer set
DHCR684–703 (5
′-[-21M13]-TCG GGA AGT GGT TTG
ACT TC-3′) and DHCR1563–1544 (5
′-[M13rev]-GGG CTC
TCT CCA GTT TAC AG-3′). For patient 3 and the par-
ents who appeared heterozygous for the 134-bp inser-
tion, different primer sets were used, which enabled us
to amplify the two cDNAs separately. The cDNA con-
taining the insert was amplified by means of primers
DHCR58 to 38 and DHCR1563–1544 in combination with
primers designed on the basis of the insert sequence (5′-
[M13rev]-GTC AAG CGG TGC TTT GCC C-3′ and 5′-
[-21M13]-CGT GTG TCA GAG GCA GAG C-3′, re-
spectively). The cDNA without the insert was amplified
by means of primers DHCR58 to 38 and DHCR1563–1544
in combination with primers spanning the site of inser-
tion, which is after nucleotide 963 (primers 5′-[M13rev]-
ACA CCA AGT ACA GAC CCT GC-3′ and 5′-[-
21M13rev]-CTT TAC ACG CTG CAG GGT C-3′,
respectively). PCR fragments were sequenced in both
directions by means of -21M13 and M13rev fluorescent
primers, on an Applied Biosystems 377A automated
DNA sequencer, according to the manufacturer’s pro-
tocol (Perkin-Elmer).
Chromosomal Mapping of 7-DHCR cDNA
FISH mapping was performed on lymphocytes by
SeeDNA Biotech, using the cDNA insert from EST clone
417125 as a probe (Heng et al. 1992; Heng and Tsui
1993). The assignment of the FISH mapping data to
chromosomal bands was achieved by superimposition
of FISH signals onto 6-diamidino-2-phenylindole
(DAPI)-banded chromosomes (Heng and Tsui 1993).
The detailed chromosomal position was determined on
the basis of the data summarized from 10 photos.
Results
Identification of the Human 7-DHCR cDNA
To identify the 7-DHCR gene, we used the BLAST
algorithm (Altschul et al. 1990) to search the database
of ESTs from the National Center for Biotechnology
Information, for sequences homologous to that of sterol
D7-reductase of Arabidopsis thaliana. This sterol D7-
reductase recently has been cloned by metabolic inter-
ference in S. cerevisiae, based on the ability of the re-
ductase to reduce the D7 double bond of ergosterol (er-
gosta-5,7,22-trien-3b-ol), the final product in the
sterol-biosynthesis pathway in yeast, which produces
brassicasterol (ergosta-5,22-dien-3b-ol) (Lecain et al.
1996). The BLAST search identified numerous human
ESTs with significant homology to the A. thaliana se-
quence representing transcripts from three different
genes. The first set of sequence codes for the human
lamin B receptor (Ye and Worman 1994), a protein con-
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Figure 3 GC/MS analysis of total sterols of S. cerevisiae transformants. A, Sterol analysis of S. cerevisiae strain transformed with pYES2
 7-DHCR and grown on glucose (GAL1-promoter repression). B, Sterol analysis of S. cerevisiae strain transformed with pYES2  7-DHCR
and grown on galactose (GAL1-promoter induction). C, Homogenate of glucose-grown S. cerevisiae strain transformed with pYES2 7-DHCR
incubated with 7-dehydrocholesterol and NADPH (GAL1-promoter repression). D, Homogenate of galactose-grown S. cerevisiae strain trans-
formed with pYES2  7-DHCR incubated with 7-dehydrocholesterol and NADPH (GAL1 promoter induction). Brassica  brassicasterol; and
5,7DHC  7-dehydrocholesterol.
sisting of an N-terminal DNA-binding domain and a C-
terminal domain of ∼440 amino acids with striking ho-
mology to the amino acid sequences of various sterol
reductases (Lecain et al. 1996). The two other sets of
ESTs are derived from two previously unidentified genes.
On the basis of the significant homology to several fun-
gal sterol D14-reductases, the second set of ESTs most
likely belongs to a gene coding for human sterol D14-
reductase, an enzyme that catalyzes the reduction of 4,4-
dimethylcholesta-8,14,24-trien-3b-ol to produce 4,4-di-
methylcholesta-8,24-dien-3b-ol (authors’ unpublished
data). The primary sequence encoded by the third set of
ESTs was found to be most homologous to A. thaliana
sterol D7-reductase, suggesting that the corresponding
gene codes for 7-DHCR.
Assembly of the putative 7-DHCR ESTs produced
only a partial transcript, of 1,880 bp. The remaining 5′
sequences were obtained by sequencing of two EST
clones for which no 5′ end sequences had been deposited
into the database and by 5′ RACE using leukocyte
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Table 3
Mutation Analysis of Patients with SLO Syndrome and of
Their Parents
cDNA Source Mutationa Coding Effect
Family of patient 1:
Patient 1 A356T () His119rLeu
G730A () Gly244rArg
Mother A356T () His119rLeu
Father G730A () Gly244rArg
Family of patient 2:
Patient 2 G963f134 bpb () Frameshift
Mother G963f134 bpb () Frameshift
Father G963f134 bpb () Frameshift
Family of patient 3:
Patient 3 G744T () Trp248rCys
G963f134 bpb () Frameshift
Mother G963f134 bpb () Frameshift
Father G744T () Trp248rCys
a   Heterozygous for mutation; and   homozy-
gous for mutation.
b The sequence of the 134-bp insert is 5′-AAG AGA ACA
CGG AGG CAA GGC GTG TGT CAG AGG CAG AGC TGG
GGT TTG ACC CCA GGC CGC TGG GCC CTC GAG CCC
ACA CTC CTG TCC TCT CCC TGG GCA AAG CAC CGC
TTG ACC CCT TCC CCC TCG CCC CCC AC-3′.
Figure 4 Chromosomal localization of human 7-DHCR gene.
A,Diagram of FISH mapping results, based on a summary of 10 photos
showing 11q13 as the chromosomal localization of the 7-DHCR gene.
Each dot represents FISH signals detected on human chromosome 11.
B, Example of FISH signal of 7-DHCR cDNA probe on chromosome
11.
cDNA. The resulting 2,385-bp cDNA (GenBank acces-
sion number AF067127) contains an open reading frame
of 1,425 bp coding for a polypeptide of 475 amino acids
(fig. 1) with a calculated molecular weight of 54.5 kD
and predicted to contain nine transmembrane-spanning
helices. The 5′ UTR and the 3′ UTR are 102 and 942
bp long, respectively. Alignment of the deduced 7-DHCR
amino acid sequence, the A. thaliana sterol D7-reduc-
tase, the C-terminal 447 amino acids from human lamin
B receptor, and different sterol reductases from S. cer-
evisiae reveals a high degree of homology among all
reductases (also see Lecain et al. 1996), with the 7-
DHCR sequence being most homologous to that of A.
thaliana sterol D7-reductase (table 1 and fig. 2).
Heterologous Expression of 7-DHCR cDNA in S.
cerevisiae
The identified transcript was shown to code for 7-
DHCR, by expression of the open reading frame under
transcriptional control of the galactose-inducible GAL1
promoter in S. cerevisiae, an organism devoid of en-
dogenous sterol D7-reductase activity. Sterol analysis of
yeast cells transformed by the expression construct
pYES2 7-DHCR and grown on glucose to fully repress
GAL1 promoter transcription identified ergosterol (er-
gosta-5,7,22-trien-3b-ol) as the main sterol, whereas no
brassicasterol (ergosta-5,22-dien-3b-ol) was detected
(table 2 and fig. 3A). However, in the same transfor-
mants grown on galactose, only 42% of the total sterol
content consisted of ergosterol, whereas 43% of the total
sterol content consisted of brassicasterol, the expected
product of the D7-reductase reaction (table 2 and fig.
3B). In addition, campesterol (ergosta-5-en-3b-ol) was
detected (15%), as also was observed after heterologous
expression of the A. thaliana sterol D7-reductase in S.
cerevisiae (Lecain et al. 1996), which suggests that the
sterol D7-reductases have some affinity for the D22 dou-
ble bond. As a control, in yeast cells transformed with
the expression vector without insert, no change in the
sterol content was observed after growth on galactose,
compared with that observed after growth on glucose
(table 2).
Additional evidence was obtained from the in vitro
conversion of 7-dehydrocholesterol (cholesta-5,7-dien-
3b-ol) to cholesterol (cholesta-5-en-3b-ol) by a homog-
enate prepared from galactose-grown cells transformed
with the expression construct (fig. 3D), which did not
occur with a homogenate from glucose-grown cells (fig.
3C).
Sequence Analysis of 7-DHCR cDNA in Patients with
SLO Syndrome
To establish that SLO syndrome is caused by muta-
tions in the gene coding for 7-DHCR, we analyzed 7-
DHCR cDNA obtained, by reverse-transcription–PCR
(RT-PCR), from skin-fibroblast RNA from three patients
with SLO syndrome. Sequence analysis of 7-DHCR
cDNA from patient 1 showed that he is compound het-
erozygous for two different point mutations. The first
mutation, A356T, changes the histidine at position 119
into a leucine, and the second mutation, G730A, changes
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the glycine at position 244, which is highly conserved
among reductases (fig. 2), into an arginine (table 3).
Analysis of 7-DHCR cDNA from the patient’s parents
revealed that the patient had inherited the A356T allele
from his mother and had inherited the G730A allele
from his father (table 3).
Sequence analysis of 7-DHCR cDNA from patient 2
showed a homozygous 134-bp insertion after nucleotide
963 (fig. 1), which causes a frameshift resulting in a
truncated protein with a changed C-terminus (table 3).
The more severely expressed phenotype of this patient
(SLO syndrome type II) is in accordance with the fact
that this 134-bp insertion occurs in a region strongly
conserved among sterol reductases (fig. 2). The homo-
zygosity of the 134-bp insertion in this patient was con-
firmed by the observation that both parents were het-
erozygous for the same insertion (table 3).
Sequence analysis of 7-DHCR cDNA from patient 3
showed that he is compound heterozygous for a point
mutation, G744T, and for the same 134-bp insertion as
was observed in patient 2 (table 3). The point mutation
is inherited from the patient’s father and changes the
tryptophan at position 248, highly conserved among
sterol reductases (fig. 2), into a cysteine. The insertion
mutation is inherited from the patient’s mother and in-
troduces a frameshift, as has been discussed for patient
2 (table 3).
Chromosomal Mapping of 7-DHCR Gene
FISH mapping experiments were performed to deter-
mine the chromosomal localization of the 7-DHCR
gene, with 7-DHCR cDNA used as a probe. The results
showed that the 7-DHCR gene is localized on chro-
mosome 11q13 (fig. 4).
Discussion
In this report we have shown that the gene coding for
7-DHCR is responsible for SLO syndrome. In addition
to the high homology of the encoded amino acid se-
quence to the sterol D7-reductase of A. thaliana, the
evidence comes from the reduction of both the C7-C8
(D7) double bond of ergosterol in vivo and of 7-dehy-
drocholesterol in vitro observed after heterologous ex-
pression of the 7-DHCR cDNA in S. cerevisiae. The
ability of human 7-DHCR to use the fungal ergosterol
as a substrate is well documented, and its use to measure
7-DHCR activities has been proposed as an alternative
method for the diagnosis of SLO syndrome (Honda et
al. 1996). During the final stages in the preparation of
the manuscript of the present article, a report appeared
that describes both the molecular cloning of the human
delta 7-sterol reductase cDNA and its heterologous ex-
pression in yeast and that leads to conclusions similar
to ours (Moebius et al. 1998). Comparison of the amino
acid sequences confirmed that the reported delta 7-sterol
reductase is identical to 7-DHCR.
The identification of distinct mutations in 7-DHCR
cDNAs from different patients with SLO syndrome dem-
onstrates that SLO syndrome is caused by mutations in
the 7-DHCR gene itself, although it still may be possible
that mutations in other genes lead to the same clinical
phenotype. Furthermore, we have shown that both the
type I (patients 1 and 3) and the more severe type II
(patient 2) forms of SLO syndrome are due to mutations
in the same gene. In fact, our results suggest a correlation
between the severity of the disease and the type of mu-
tation. Both patients with SLO syndrome type I are com-
pound heterozygous for missense mutations that result
in mutated 7-DHCR proteins that still may have suffi-
cient residual activity to support life. On the other hand,
the homozygous 134-bp insertion found in the patient
with SLO syndrome type II produces a truncated 7-
DHCR protein lacking 154 amino acids of its original
C-terminal sequence. On the basis of the fact that this
C terminus is highly conserved among sterol reductases
(fig. 2), the resulting protein is not expected to be
functional.
Interestingly, the 134-bp insertion mutation is ob-
served in two of the three patients in the present report.
Since neither these patients nor their parents are related
to each other, this suggests that the 134-bp insertion may
be a more frequently occurring mutation. Indeed, RT-
PCR analysis of 7-DHCR cDNA from three additional
unrelated patients with SLO syndrome identified two
more cases of (compound) heterozygosity for the 134-
bp insertion (authors’ unpublished results). Analysis at
the genomic level will be necessary in order to determine
whether this insertion is caused by a splice-site mutation.
On the basis of a single de novo chromosomal trans-
location event observed in a patient diagnosed with SLO
syndrome type II, chromosome 7q32 has been suggested
as a candidate location for the gene responsible for SLO
syndrome (Wallace et al. 1994; Alley et al. 1995, 1997).
However, the results of the FISH mapping experiments
reveal that the 7-DHCR gene is localized on chromo-
some 11q13. A possible explanation for the discrepancy
may be that the chromosomal translocation event is not
directly related to the clinical manifestations in the pa-
tient. Since the elevated concentration of 7-dehydrocho-
lesterol in fibroblasts of the patient suggests that the 7-
DHCR gene is affected, sequence analysis of fibroblast
7-DHCR cDNA of the patient will be the first logical
step to take to resolve this matter.
Recently, we have identified a full-length cDNA cod-
ing for mouse 7-DHCR, which will be used to create an
animal model for SLO syndrome. An animal SLO-syn-
drome model will enable us to study not only the effects
of different cholesterol-enriched regimens but also why
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lowered cholesterol and elevated 7-dehydrocholesterol
levels cause the variable SLO phenotypes. In this respect,
it will be of particular interest to study the function of
embryonic signaling proteins, such as sonic hedgehog
protein, that are crucial for early development and the
spatial distributions of which are determined by choles-
terol (Kelley et al. 1996; Porter et al. 1996; Lanoue et
al. 1997; Tabin and McMahon 1997; Farese and Herz
1998).
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